Your browser doesn't support javascript.
loading
Complementary and Alternative Therapy Use in Children with Cerebral Palsy.
Oskoui, Maryam; Ng, Pamela; Zaman, Michele; Buckley, David; Kirton, Adam; van Rensburg, Esias; Wood, Ellen; Shevell, Michael; Majnemer, Annette.
Afiliação
  • Oskoui M; Department of Pediatrics, McGill University, Montreal, QC, Canada.
  • Ng P; Department of Neurology and Neurosurgery, McGill University, Montreal, QC, Canada.
  • Zaman M; Centre for Outcomes Research and Evaluation, Research Institute of the McGill University Health Centre, Montreal, QC, Canada.
  • Buckley D; Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, QC, Canada.
  • Kirton A; Janeway Children's Hospital, St. John's, NL, Canada.
  • van Rensburg E; Departments of Pediatrics and Clinical Neurosciences, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada.
  • Wood E; BC Children's Hospital, Vancouver, BC, Canada.
  • Shevell M; IWK Health Centre, Halifax, NS, Canada.
  • Majnemer A; Department of Pediatrics, McGill University, Montreal, QC, Canada.
Can J Neurol Sci ; 48(3): 408-414, 2021 05.
Article em En | MEDLINE | ID: mdl-32854793
ABSTRACT

OBJECTIVE:

To describe complementary and alternative medicine (CAM) use amongst children with cerebral palsy (CP) in Canada and to identify factors associated with CAM use.

METHODS:

We conducted a cross-sectional study, utilising data from the Canadian CP Registry. We explored the association between CAM use and regional, socioeconomic and CP phenotypic variables, and parental perception of the family-centredness of clinical care using the Measures of Process of Care-56 (MPOC-56). Chi-square analyses were performed, and odds ratios (OR) and 95% confidence intervals (CI) were obtained. Mann-Whitney U tests were used to compare MPOC-56 scores between CAM users and non-CAM users.

RESULTS:

The study sample consisted of 313 families of which 27% reported CAM use in the past year. Children with CP using CAM were more likely to reside in Western Canada (OR 3.3, 95% CI 1.6-6.7), live in a two-parent household (OR 3.5, 95% CI 1.5-8.4), have an ataxic/hypotonic or dyskinetic CP subtype (OR 3.0, 95% CI 1.5-6.1) and have a greater motor impairment (OR 2.8, 95% CI 1.7-4.9). MPOC-56 subscale scores were not significantly associated with CAM use.

CONCLUSION:

Physicians need to be aware of existing CAM therapies, the level of evidence supporting their efficacy (beneficence), their associated risks of adverse events (non-maleficence) and enable fair access to care that may be of benefit to each child.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Terapias Complementares / Paralisia Cerebral Tipo de estudo: Observational_studies / Prevalence_studies / Prognostic_studies / Risk_factors_studies Limite: Child / Humans País como assunto: America do norte Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Terapias Complementares / Paralisia Cerebral Tipo de estudo: Observational_studies / Prevalence_studies / Prognostic_studies / Risk_factors_studies Limite: Child / Humans País como assunto: America do norte Idioma: En Ano de publicação: 2021 Tipo de documento: Article